Director/PDMR Shareholding

RNS Number : 1777R
GlaxoSmithKline PLC
12 June 2018
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.4154

8 (partnership shares)

£15.4154

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.4154

 

 

e)

Date of the transaction

2018-06-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.4154

8 (partnership shares)

£15.4154

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.4154

 

 

e)

Date of the transaction

2018-06-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.4154

8 (partnership shares)

£15.4154

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.4154

 

 

e)

Date of the transaction

2018-06-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.4154

8 (partnership shares)

£15.4154

8(matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.4154

 

 

e)

Date of the transaction

2018-06-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

   

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.4154

8 (partnership shares)

£15.4154

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.4154

 

 

e)

Date of the transaction

2018-06-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

  

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.  

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.4154

8 (partnership shares)

£15.4154

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.4154

 

 

e)

Date of the transaction

2018-06-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.4154

8 (partnership shares)

£15.4154

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.4154

 

 

e)

Date of the transaction

2018-06-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.4154

8 (partnership shares)

£15.4154

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.4154

 

 

e)

Date of the transaction

2018-06-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs V A Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.4154

8 (partnership shares)

£15.4154

8 (matching shares)

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£15.4154

 

 

e)

Date of the transaction

2018-06-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHQLLFFVQFFBBL

Companies

GSK (GSK)
UK 100

Latest directors dealings